uracil has been researched along with Cardiac Failure in 29 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
| Excerpt | Relevance | Reference |
|---|---|---|
| "In patients with type 2 diabetes and recent acute coronary syndromes, alogliptin did not increase the risk of heart failure outcomes." | 9.20 | Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. ( Bakris, GL; Cannon, CP; Cushman, WC; Fleck, PR; Kupfer, S; Lam, H; Mehta, CR; Menon, V; Perez, AT; White, WB; Wilson, C; Zannad, F, 2015) |
| "In patients with type 2 diabetes and recent acute coronary syndromes, alogliptin did not increase the risk of heart failure outcomes." | 5.20 | Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. ( Bakris, GL; Cannon, CP; Cushman, WC; Fleck, PR; Kupfer, S; Lam, H; Mehta, CR; Menon, V; Perez, AT; White, WB; Wilson, C; Zannad, F, 2015) |
| "There are data from studies using sitagliptin, saxagliptin, and alogliptin showing that these agents may increase the risk of hospitalization for heart failure." | 4.90 | Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure? ( Clifton, P, 2014) |
| " In the cardiovascular subset, there was an SDR for heart failure with linagliptin (EB05 = 2782." | 3.88 | Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: A disproportionality analysis among high-risk patients. ( Alexander, GC; Baksh, SN; McAdams-DeMarco, M; Segal, JB, 2018) |
| "We investigated the effects of a DPP-4 inhibitor, alogliptin, on atrial fibrillation (AF) in a rabbit model of heart failure caused by ventricular tachypacing (VTP)." | 3.81 | Alogliptin, a dipeptidyl peptidase-4 inhibitor, regulates the atrial arrhythmogenic substrate in rabbits. ( Hirai, M; Inden, Y; Murohara, T; Shimano, M; Takefuji, M; Tsuji, Y; Yamamoto, T; Yanagisawa, S; Yoshida, N, 2015) |
| "Early after an ACS, patients with type 2 diabetes mellitus experience a significant burden of HF events and recurrent ACS." | 2.87 | Early and Chronic Dipeptidyl-Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial. ( Bakris, GL; Cannon, CP; Cushman, WC; Liu, Y; Sharma, A; White, WB; Zannad, F, 2018) |
| "Conclusions In patients with type 2 diabetes mellitus and recent acute coronary syndrome, average BP s <130/80 mm Hg were associated with worsened cardiovascular outcomes." | 2.87 | Average Clinician-Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial. ( Bakris, GL; Bergenstal, R; Cannon, CP; Cushman, WC; Heller, SR; Jalil, F; Liu, Y; Mehta, C; White, WB; Zannad, F, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (17.24) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (6.90) | 29.6817 |
| 2010's | 18 (62.07) | 24.3611 |
| 2020's | 4 (13.79) | 2.80 |
| Authors | Studies |
|---|---|
| Sharma, A | 2 |
| Vaduganathan, M | 1 |
| Ferreira, JP | 1 |
| Liu, Y | 4 |
| Bakris, GL | 5 |
| Cannon, CP | 5 |
| White, WB | 7 |
| Zannad, F | 6 |
| Nabavizadeh, P | 1 |
| Steen, DL | 1 |
| Shen, S | 1 |
| Sewanan, LR | 1 |
| Campbell, SG | 1 |
| Chen, YJ | 1 |
| Chien, CS | 1 |
| Chiang, CE | 1 |
| Chen, CH | 1 |
| Cheng, HM | 1 |
| Kaneko, M | 1 |
| Narukawa, M | 1 |
| Hwang, YC | 1 |
| Morrow, DA | 1 |
| Bergenstal, R | 2 |
| Heller, S | 1 |
| Mehta, C | 2 |
| Cushman, W | 1 |
| Baksh, SN | 1 |
| McAdams-DeMarco, M | 1 |
| Segal, JB | 1 |
| Alexander, GC | 1 |
| Cushman, WC | 3 |
| Sano, M | 1 |
| Jalil, F | 1 |
| Heller, SR | 1 |
| Clifton, P | 1 |
| Yamamoto, T | 1 |
| Shimano, M | 1 |
| Inden, Y | 1 |
| Takefuji, M | 1 |
| Yanagisawa, S | 1 |
| Yoshida, N | 1 |
| Tsuji, Y | 1 |
| Hirai, M | 1 |
| Murohara, T | 2 |
| Menon, V | 1 |
| Perez, AT | 1 |
| Fleck, PR | 1 |
| Mehta, CR | 1 |
| Kupfer, S | 2 |
| Wilson, C | 1 |
| Lam, H | 1 |
| Riche, DM | 1 |
| Davis, C | 1 |
| Derosa, G | 1 |
| Maffioli, P | 1 |
| Hülsmann, M | 1 |
| Pacher, R | 1 |
| Neuhold, S | 1 |
| Špinar, J | 1 |
| Špinarová, L | 1 |
| Vítovec, J | 1 |
| Aoyama, M | 1 |
| Kawase, H | 1 |
| Bando, YK | 1 |
| Monji, A | 1 |
| Baker, WL | 1 |
| Jermendy, G | 1 |
| Schernthaner, G | 1 |
| Cahn, A | 1 |
| Raz, I | 1 |
| HELLMAN, E | 1 |
| ALTCHEK, R | 1 |
| ENSELBERG, CD | 1 |
| GILBERT, RP | 1 |
| FLACK, HA | 1 |
| Yajima, T | 1 |
| Furukawa, Y | 1 |
| Ishii, Y | 1 |
| Hattori, Y | 1 |
| Matsumoto, N | 1 |
| Yamamoto, M | 1 |
| Yamaoka, Y | 1 |
| Fujihara, M | 1 |
| Fujita, M | 1 |
| Kuniki, H | 1 |
| Branca, MA | 1 |
| Meerson, FZ | 1 |
| Buckley, NM | 1 |
| Kapel'ko, VI | 1 |
| Shenderov, SM | 1 |
| Klykov, NV | 1 |
| Sánchez, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment With Alogliptin in Addition to Standard of Care in Subjects With Type 2 Diabetes and Acute Coronary Syndrome[NCT00968708] | Phase 3 | 5,380 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Primary Major Adverse Cardiac Events were defined as a composite of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke; these events were adjudicated by an independent cardiovascular endpoints committee. (NCT00968708)
Timeframe: From randomization until the adjudication cut-off date of May 31 2013 (maximum time on study was 41 months).
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 11.8 |
| Alogliptin | 11.3 |
Secondary MACE composite consisted of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or urgent revascularization due to unstable angina; these events were adjudicated by an independent cardiovascular endpoint committee. (NCT00968708)
Timeframe: From randomization until the adjudication cut-of date of May 31 2013 (maximum time on study was 41 months).
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 13.4 |
| Alogliptin | 12.7 |
7 reviews available for uracil and Cardiac Failure
| Article | Year |
|---|---|
From Genetic Mutations to Molecular Basis of Heart Failure Treatment: An Overview of the Mechanism and Implication of the Novel Modulators for Cardiac Myosin.
Topics: Benzylamines; Cardiac Myosins; Heart Failure; Humans; Molecular Targeted Therapy; Myocytes, Cardiac; | 2021 |
Mechanism by which dipeptidyl peptidase-4 inhibitors increase the risk of heart failure and possible differences in heart failure risk.
Topics: Adult; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Femal | 2019 |
Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Heart Failure | 2014 |
[The TECOS, EXAMINE and SAVOR studies--how do they differ and what are their outcomes?].
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors | 2015 |
Cardiovascular Effects of Incretin-Based Therapies.
Topics: Adamantane; Cardiovascular Diseases; Cardiovascular System; Clinical Trials as Topic; Diabetes Melli | 2016 |
[Cardiovascular safety of incretin-based antidiabetic treatment - results of completed clinical trials].
Topics: Adamantane; Cardiovascular System; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV In | 2016 |
[Depletion therapy of chronic congestive heart failure].
Topics: Bloodletting; Carbonic Anhydrase Inhibitors; Chlorides; Diet, Sodium-Restricted; Digitalis Glycoside | 1968 |
5 trials available for uracil and Cardiac Failure
17 other studies available for uracil and Cardiac Failure
| Article | Year |
|---|---|
Highlights from the European society of cardiology congress 2020.
Topics: Atrial Fibrillation; Benzhydryl Compounds; Benzylamines; Cardiomyopathy, Hypertrophic; Cardiovascula | 2021 |
Evidence for synergy between sarcomeres and fibroblasts in an in vitro model of myocardial reverse remodeling.
Topics: Actomyosin; Animals; Animals, Newborn; Benzamides; Benzylamines; Cardiac Myosins; Cell Line; Dioxole | 2021 |
Assessment of the Risk of Hospitalization for Heart Failure With Dipeptidyl Peptidase-4 Inhibitors, Saxagliptin, Alogliptin, and Sitagliptin in Patients With Type 2 Diabetes, Using an Alternative Measure to the Hazard Ratio.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Heart Failure | 2017 |
Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: A disproportionality analysis among high-risk patients.
Topics: Adamantane; Administration, Oral; Adverse Drug Reaction Reporting Systems; Aged; Bayes Theorem; Data | 2018 |
Alogliptin, a dipeptidyl peptidase-4 inhibitor, regulates the atrial arrhythmogenic substrate in rabbits.
Topics: Animals; Atrial Fibrillation; Blotting, Western; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; E | 2015 |
EXAMINE: targeting risk and treatment in diabetes.
Topics: Acute Coronary Syndrome; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Female; Heart Failure | 2015 |
EXAMINE: targeting risk and treatment in diabetes.
Topics: Acute Coronary Syndrome; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Female; Heart Failure | 2015 |
EXAMINE: targeting risk and treatment in diabetes.
Topics: Acute Coronary Syndrome; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Female; Heart Failure | 2015 |
EXAMINE: targeting risk and treatment in diabetes - Authors' reply.
Topics: Acute Coronary Syndrome; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Female; Heart Failure | 2015 |
Dipeptidyl Peptidase 4 Inhibition Alleviates Shortage of Circulating Glucagon-Like Peptide-1 in Heart Failure and Mitigates Myocardial Remodeling and Apoptosis via the Exchange Protein Directly Activated by Cyclic AMP 1/Ras-Related Protein 1 Axis.
Topics: Animals; Apoptosis; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Dipeptidyl Peptidase 4; Dipept | 2016 |
Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS.
Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV | 2016 |
Therapeutic and toxic effects of a new oral diuretic (1-propyl-3-ethyl-6-aminouracil).
Topics: Diuretics; Heart Failure; Humans; Uracil; Wounds and Injuries | 1952 |
A therapeutic evaluation of four aminouracil compounds.
Topics: Diuretics; Heart Failure; Uracil | 1953 |
[Two cases of advanced pancreatic cancer responding to gemcitabine with long survival of 2 years].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cholestasis; Deoxycytidine; Drug Ad | 2004 |
BiDil raises questions about race as a marker.
Topics: Biomarkers; Black People; Clinical Trials as Topic; Dihydropyrimidine Dehydrogenase Deficiency; Dihy | 2005 |
[Effect of nucleosides on the contractile function of the myocardium in the emergency stage of compensatory function of the heart].
Topics: Animals; Aortic Diseases; Heart Failure; Heart Ventricles; Hypoxanthines; Male; Nucleosides; Rabbits | 1966 |
[Use of pentoxyl in the treatment of chronic cardiac insufficiency].
Topics: Adult; Aged; Chronic Disease; Drug Synergism; Female; Heart Failure; Humans; Male; Middle Aged; Rheu | 1975 |